Nanostar Biosensors Use Raman Scattering for Direct Detection of Cancer-Related MicroRNAs
|
By LabMedica International staff writers Posted on 03 Aug 2020 |

Image: Micrograph of gold nanostar biosensors used to detect cancer-related microRNAs (Photo courtesy of Duke University School of Engineering)
A novel non-invasive nanoparticle-based assay detects cancer-related microRNAs without use of labels or target amplification.
MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions. However, due to technical difficulties in detecting these small molecules, miRNAs have not been adopted into routine clinical practice for early diagnostics. Thus, it is important to develop alternative detection strategies that could offer more advantages over conventional methods.
In this regard, investigators at Duke University (Durham, NC, USA) developed nanophotonics technology termed "the inverse molecular sentinel (iMS) nanobiosensor, with surface-enhanced Raman scattering (SERS) detection".
The iMS-SERS technique is based on plasmonics, which refers to the enhanced electromagnetic properties of metallic nanostructures. The term plasmonics is derived from "plasmons", which are the quanta associated with longitudinal waves propagating in matter through the collective motion of large numbers of electrons. Incident light, usually from a laser, irradiating these surfaces excites conduction electrons in the metal, and induces excitation of surface plasmons leading to enormous electromagnetic enhancement of spectral signature, such as surface-enhanced Raman scattering (SERS) and surface-enhanced fluorescence (SEF) for ultrasensitive detection of chemical and biological species.
The SERS nanoprobe used in the current study relied on plasmonic-active nanostars as the sensing platform. An “OFF-to-ON” signal switch was based on a nonenzymatic strand-displacement process and the conformational change of stem-loop (hairpin) oligonucleotide probes upon target binding. This technique was used previously to detect a synthetic DNA sequence of interest. In this study, the design of the nanoprobe was modified to be used for the detection of short miRNA sequences.
In the current study, the investigators found that the iMS-SERS nanostar method detected miR-21, the microRNA biomarker linked to esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE), the premalignant metaplasia associated with EAC. This approach enabled the direct detection of the esophageal cancer biomarker in RNA extracted from 17 endoscopic tissue biopsies. Thus, the potential of this label-free, homogeneous biosensor for cancer diagnosis without the need for target amplification was demonstrated by discriminating esophageal cancer and Barrett's esophagus from normal tissue with notable diagnostic accuracy.
"Gold nanostars have multiple spikes that can act as lighting rods for enhancing electromagnetic waves, which is a unique feature of the particle's shape," said senior author Dr. Tuan Vo-Dinh, professor of biomedical engineering at Duke University. "Our tiny nanosensors, called "inverse molecular sentinels", take advantage of this ability to create clear signals of the presence of multiple microRNAs. The Raman signals of label molecules exhibit sharp peaks with very specific colors like spectral fingerprints that make them easily distinguished from one another when detected. Thus we can actually design different sensors for different microRNAs on nanostars, each with label molecules exhibiting their own specific spectral fingerprints. And because the signal is so strong, we can detect each one of these fingerprints independently of each other."
"The general research focus in my lab has been on the early detection of diseases in people before they even know they are sick," said Dr.Vo-Dinh. "And to do that, you need to be able to go upstream, at the genomic level, to look at biomarkers like microRNA."
The gold nanostar paper was published in the May 4, 2020, online edition of the journal Analyst.
Related Links:
Duke University
MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions. However, due to technical difficulties in detecting these small molecules, miRNAs have not been adopted into routine clinical practice for early diagnostics. Thus, it is important to develop alternative detection strategies that could offer more advantages over conventional methods.
In this regard, investigators at Duke University (Durham, NC, USA) developed nanophotonics technology termed "the inverse molecular sentinel (iMS) nanobiosensor, with surface-enhanced Raman scattering (SERS) detection".
The iMS-SERS technique is based on plasmonics, which refers to the enhanced electromagnetic properties of metallic nanostructures. The term plasmonics is derived from "plasmons", which are the quanta associated with longitudinal waves propagating in matter through the collective motion of large numbers of electrons. Incident light, usually from a laser, irradiating these surfaces excites conduction electrons in the metal, and induces excitation of surface plasmons leading to enormous electromagnetic enhancement of spectral signature, such as surface-enhanced Raman scattering (SERS) and surface-enhanced fluorescence (SEF) for ultrasensitive detection of chemical and biological species.
The SERS nanoprobe used in the current study relied on plasmonic-active nanostars as the sensing platform. An “OFF-to-ON” signal switch was based on a nonenzymatic strand-displacement process and the conformational change of stem-loop (hairpin) oligonucleotide probes upon target binding. This technique was used previously to detect a synthetic DNA sequence of interest. In this study, the design of the nanoprobe was modified to be used for the detection of short miRNA sequences.
In the current study, the investigators found that the iMS-SERS nanostar method detected miR-21, the microRNA biomarker linked to esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE), the premalignant metaplasia associated with EAC. This approach enabled the direct detection of the esophageal cancer biomarker in RNA extracted from 17 endoscopic tissue biopsies. Thus, the potential of this label-free, homogeneous biosensor for cancer diagnosis without the need for target amplification was demonstrated by discriminating esophageal cancer and Barrett's esophagus from normal tissue with notable diagnostic accuracy.
"Gold nanostars have multiple spikes that can act as lighting rods for enhancing electromagnetic waves, which is a unique feature of the particle's shape," said senior author Dr. Tuan Vo-Dinh, professor of biomedical engineering at Duke University. "Our tiny nanosensors, called "inverse molecular sentinels", take advantage of this ability to create clear signals of the presence of multiple microRNAs. The Raman signals of label molecules exhibit sharp peaks with very specific colors like spectral fingerprints that make them easily distinguished from one another when detected. Thus we can actually design different sensors for different microRNAs on nanostars, each with label molecules exhibiting their own specific spectral fingerprints. And because the signal is so strong, we can detect each one of these fingerprints independently of each other."
"The general research focus in my lab has been on the early detection of diseases in people before they even know they are sick," said Dr.Vo-Dinh. "And to do that, you need to be able to go upstream, at the genomic level, to look at biomarkers like microRNA."
The gold nanostar paper was published in the May 4, 2020, online edition of the journal Analyst.
Related Links:
Duke University
Latest Molecular Diagnostics News
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







